RNAC

Cartesian Therapeutics, Inc. Common Stock

$6.92 -8.22%

Recent alerts on RNAC

All signals →

SEC filing RNAC Secures up to $150M Non-Dilutive Financing, Extends Cash Runway into 2028, Anticipates Multiple Clinical Catalysts in 2027

News AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate

News US Stocks Futures Trade Mixed Ahead Of Opening Bell: 'Preserve Capital In Conditions Of High Uncertainty,' Says Expert

News Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates - Zacks Investment Research

News Cartesian (RNAC) Up as FDA Grants RMAT Tag to Descartes-08

SEC filing RNAC Reports $120.4M Cash, $19.5M R&D, Initiates Phase 2 TRITON Myositis Trial, Enrolls Pediatric JDM in HELIOS, Supports Ops to Mid‑2027

SEC filing RNAC Reports $126.9M Cash, Phase 3 AURORA Trial Enrollment Progress, FDA Accepts TRITON IND, HELIOS Pediatric Trial Ongoing

News Rush Enterprises sees Class 8 order momentum carrying into 2026 as industry clarity returns

Scanner Unusual volume (3.1x average)

News Johnson & Johnson Touts Encouraging Results For Experimental Lupus Treatment

Get push alerts for RNAC

Add it to your watchlist in the app and receive every signal the moment it fires.

Download for iOS

Download for iOS